Literature DB >> 20232353

Mucopolysaccharidosis type IIID: 12 new patients and 15 novel mutations.

Marlies J Valstar1, Aida M Bertoli-Avella, Marja W Wessels, George J G Ruijter, Bianca de Graaf, Renske Olmer, Peter Elfferich, Sanne Neijs, Roxana Kariminejad, Fatih Suheyl Ezgü, Aysegul Tokatli, Barbara Czartoryska, Ad N Bosschaart, Feikje van den Bos-Terpstra, Hugues Puissant, Friederike Bürger, Heymut Omran, D Eckert, Mirella Filocamo, Emil Simeonov, Patrick J Willems, Ron A Wevers, Martinus F Niermeijer, Dicky J J Halley, Ben J H M Poorthuis, Otto P van Diggelen.   

Abstract

Mucopolysaccharidosis III D (Sanfilippo disease type D, MPS IIID) is a rare autosomal recessive lysosomal storage disorder previously described in only 20 patients. MPS IIID is caused by a deficiency of N-acetylglucosamine-6-sulphate sulphatase (GNS), one of the enzymes required for the degradation of heparan sulphate. So far only seven mutations in the GNS gene have been reported. The clinical phenotype of 12 new MPS IIID patients from 10 families was studied. Mutation analysis of GNS was performed in 16 patients (14 index cases). Clinical signs and symptoms of the MPS IIID patients appeared to be similar to previously described patients with MPS III. Early development was normal with onset of behavioral problems around the age of 4 years, followed by developmental stagnation, deterioration of verbal communication and subsequent deterioration of motor functions. Sequence analysis of the coding regions of the gene encoding GNS (GNS) resulted in the identification of 15 novel mutations: 3 missense mutations, 1 nonsense mutation, 4 splice site mutations, 3 frame shift mutations, 3 large deletions and 1 in-frame small deletion. They include the first missense mutations and a relatively high proportion of large rearrangements, which warrants the inclusion of quantitative techniques in routine mutation screening of the GNS gene. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20232353     DOI: 10.1002/humu.21234

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  12 in total

1.  Epidemiology of mucopolysaccharidoses.

Authors:  Shaukat A Khan; Hira Peracha; Diana Ballhausen; Alfred Wiesbauer; Marianne Rohrbach; Matthias Gautschi; Robert W Mason; Roberto Giugliani; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2017-05-26       Impact factor: 4.797

2.  Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease.

Authors:  J de Ruijter; L Ijlst; W Kulik; H van Lenthe; T Wagemans; N van Vlies; F A Wijburg
Journal:  J Inherit Metab Dis       Date:  2012-09-12       Impact factor: 4.982

3.  Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-N-Acetylglucosamine-6-Sulfatase in Neonatal Mice.

Authors:  Feng Wang; Derek R Moen; Chelsee Sauni; Shih-Hsin Kan; Shan Li; Steven Q Le; Brett Lomenick; Xiaoyi Zhang; Sean Ekins; Srikanth Singamsetty; Jill Wood; Patricia I Dickson; Tsui-Fen Chou
Journal:  Mol Pharm       Date:  2020-12-15       Impact factor: 4.939

4.  Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III).

Authors:  Nicole M Muschol; Daniel Pape; Kai Kossow; Kurt Ullrich; Laila Arash-Kaps; Julia B Hennermann; Ralf Stücker; Sandra R Breyer
Journal:  Orphanet J Rare Dis       Date:  2019-05-02       Impact factor: 4.123

Review 5.  Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder.

Authors:  Frits A Wijburg; Grzegorz Węgrzyn; Barbara K Burton; Anna Tylki-Szymańska
Journal:  Acta Paediatr       Date:  2013-02-06       Impact factor: 2.299

Review 6.  Sanfilippo syndrome: causes, consequences, and treatments.

Authors:  Anthony O Fedele
Journal:  Appl Clin Genet       Date:  2015-11-25

7.  Mortality in patients with Sanfilippo syndrome.

Authors:  Christine Lavery; Chris J Hendriksz; Simon A Jones
Journal:  Orphanet J Rare Dis       Date:  2017-10-23       Impact factor: 4.123

Review 8.  Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions.

Authors:  Jeremy Wolfberg; Keerthana Chintalapati; Shunji Tomatsu; Kyoko Nagao
Journal:  Diagnostics (Basel)       Date:  2020-08-04

9.  Unveiling metabolic remodeling in mucopolysaccharidosis type III through integrative metabolomics and pathway analysis.

Authors:  Abdellah Tebani; Lenaig Abily-Donval; Isabelle Schmitz-Afonso; Bénédicte Héron; Monique Piraud; Jérôme Ausseil; Farid Zerimech; Bruno Gonzalez; Stéphane Marret; Carlos Afonso; Soumeya Bekri
Journal:  J Transl Med       Date:  2018-09-04       Impact factor: 5.531

Review 10.  Molecular Bases of Neurodegeneration and Cognitive Decline, the Major Burden of Sanfilippo Disease.

Authors:  Rachel Heon-Roberts; Annie L A Nguyen; Alexey V Pshezhetsky
Journal:  J Clin Med       Date:  2020-01-27       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.